000			01997 a2200541 4500
005			20250515153331.0
264		0	_c20090921
008			200909s 0 0 eng d
022			_a1095-953X
024	7		_a10.1016/j.nbd.2008.11.010 _2doi
040			_aNLM _beng _cNLM
100	1		_aVisanji, Naomi P
245	0	0	_aDopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. _h[electronic resource]
260			_bNeurobiology of disease _cAug 2009
300			_a184-92 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_a1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
650	0	4	_aAnimals
650	0	4	_aAntiparkinson Agents _xadverse effects
650	0	4	_aBenzopyrans _xpharmacology
650	0	4	_aCallithrix
650	0	4	_aCorpus Striatum _xdrug effects
650	0	4	_aDisease Models, Animal
650	0	4	_aDopamine Antagonists _xpharmacology
650	0	4	_aDopamine and cAMP-Regulated Phosphoprotein 32 _xmetabolism
650	0	4	_aDyskinesia, Drug-Induced _xetiology
650	0	4	_aEnkephalins _xmetabolism
650	0	4	_aFemale
650	0	4	_aLevodopa _xadverse effects
650	0	4	_aMale
650	0	4	_aOxidopamine
650	0	4	_aParkinsonian Disorders _xchemically induced
650	0	4	_aProtein Precursors _xmetabolism
650	0	4	_aPyrroles _xpharmacology
650	0	4	_aRNA, Messenger _xmetabolism
650	0	4	_aRats
650	0	4	_aRats, Sprague-Dawley
650	0	4	_aReceptors, Dopamine D1 _xmetabolism
650	0	4	_aReceptors, Dopamine D2 _xmetabolism
650	0	4	_aReceptors, Dopamine D3 _xantagonists & inhibitors
700	1		_aFox, Susan H
700	1		_aJohnston, Tom
700	1		_aReyes, Gabriela
700	1		_aMillan, Mark J
700	1		_aBrotchie, Jonathan M
773	0		_tNeurobiology of disease _gvol. 35 _gno. 2 _gp. 184-92
856	4	0	_uhttps://doi.org/10.1016/j.nbd.2008.11.010 _zAvailable from publisher's website
999			_c18568412 _d18568412